Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215233 | 1.00 | USP30 (0.45) | USP30ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3212260 | 0.94 | USP30 (0.42) | USP30ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3212273 | 0.94 | USP30 (0.42) | USP30ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3200648 | 0.94 | USP30 (0.48) | USP30ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3200630 | 0.94 | USP30 (0.48) | USP30ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3212715 | 0.90 | USP30 (0.46) | USP30HCRTR1HCRTR2PRCP | |
| SCHEMBL3219377 | 0.90 | USP30 (0.46) | USP30HCRTR1HCRTR2PRCP | |
| SCHEMBL3204733 | 0.89 | HCRTR1 (0.47) | ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3219085 | 0.89 | HCRTR1 (0.47) | ENPP2ATXN2HCRTR1HCRTR2 | |
| SCHEMBL3225942 | 0.89 | USP30 (0.48) | USP30HCRTR1HCRTR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | claimed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2097405-A2 | ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | USP30 4072/4885ENPP2 1731/4885ATXN2 3522/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | USP30 4072/4885ENPP2 1731/4885ATXN2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.